AP911A - Combinatin of aldose reductase inhibitor and a glycogen phosphorylase inhibitor. - Google Patents
Combinatin of aldose reductase inhibitor and a glycogen phosphorylase inhibitor. Download PDFInfo
- Publication number
- AP911A AP911A APAP/P/1998/001401A AP9801401A AP911A AP 911 A AP911 A AP 911A AP 9801401 A AP9801401 A AP 9801401A AP 911 A AP911 A AP 911A
- Authority
- AP
- ARIPO
- Prior art keywords
- alkyl
- mono
- inhibitor
- aldose reductase
- glycogen phosphorylase
- Prior art date
Links
- 239000003288 aldose reductase inhibitor Substances 0.000 title abstract description 13
- 229940118148 Aldose reductase inhibitor Drugs 0.000 title description 7
- ROJNYKZWTOHRNU-UHFFFAOYSA-N 2-chloro-4,5-difluoro-n-[[2-methoxy-5-(methylcarbamoylamino)phenyl]carbamoyl]benzamide Chemical compound CNC(=O)NC1=CC=C(OC)C(NC(=O)NC(=O)C=2C(=CC(F)=C(F)C=2)Cl)=C1 ROJNYKZWTOHRNU-UHFFFAOYSA-N 0.000 title description 5
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract description 22
- 238000011282 treatment Methods 0.000 abstract description 12
- 102000004877 Insulin Human genes 0.000 abstract description 11
- 108090001061 Insulin Proteins 0.000 abstract description 11
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 11
- 229940125396 insulin Drugs 0.000 abstract description 11
- 102000007390 Glycogen Phosphorylase Human genes 0.000 abstract description 7
- 108010046163 Glycogen Phosphorylase Proteins 0.000 abstract description 7
- 229940090865 aldose reductase inhibitors used in diabetes Drugs 0.000 abstract description 6
- 239000003112 inhibitor Substances 0.000 abstract description 5
- 208000028867 ischemia Diseases 0.000 abstract description 5
- 239000000203 mixture Substances 0.000 abstract description 4
- 238000000034 method Methods 0.000 abstract description 3
- 230000000451 tissue damage Effects 0.000 abstract description 3
- 231100000827 tissue damage Toxicity 0.000 abstract description 3
- 125000000217 alkyl group Chemical group 0.000 description 29
- -1 zopolrestat Chemical class 0.000 description 25
- 206010020772 Hypertension Diseases 0.000 description 16
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 239000008103 glucose Substances 0.000 description 10
- 125000005843 halogen group Chemical group 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 9
- 201000001320 Atherosclerosis Diseases 0.000 description 8
- 125000003545 alkoxy group Chemical group 0.000 description 8
- 230000034994 death Effects 0.000 description 8
- 231100000517 death Toxicity 0.000 description 8
- 230000002440 hepatic effect Effects 0.000 description 8
- 150000002632 lipids Chemical class 0.000 description 8
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 8
- 239000008280 blood Substances 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 230000009229 glucose formation Effects 0.000 description 7
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 230000004116 glycogenolysis Effects 0.000 description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 6
- 201000010099 disease Diseases 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 5
- 208000010125 myocardial infarction Diseases 0.000 description 5
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 5
- BCSVCWVQNOXFGL-UHFFFAOYSA-N 3,4-dihydro-4-oxo-3-((5-trifluoromethyl-2-benzothiazolyl)methyl)-1-phthalazine acetic acid Chemical compound O=C1C2=CC=CC=C2C(CC(=O)O)=NN1CC1=NC2=CC(C(F)(F)F)=CC=C2S1 BCSVCWVQNOXFGL-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 208000024172 Cardiovascular disease Diseases 0.000 description 4
- 229920002527 Glycogen Polymers 0.000 description 4
- 208000031226 Hyperlipidaemia Diseases 0.000 description 4
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 230000000747 cardiac effect Effects 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- MNQZXJOMYWMBOU-UHFFFAOYSA-N glyceraldehyde Chemical compound OCC(O)C=O MNQZXJOMYWMBOU-UHFFFAOYSA-N 0.000 description 4
- 229940096919 glycogen Drugs 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 229950005346 zopolrestat Drugs 0.000 description 4
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 3
- 125000003363 1,3,5-triazinyl group Chemical group N1=C(N=CN=C1)* 0.000 description 3
- 208000007530 Essential hypertension Diseases 0.000 description 3
- 206010019280 Heart failures Diseases 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 206010041277 Sodium retention Diseases 0.000 description 3
- 239000003472 antidiabetic agent Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 125000004093 cyano group Chemical group *C#N 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 125000002541 furyl group Chemical group 0.000 description 3
- 229940126904 hypoglycaemic agent Drugs 0.000 description 3
- 230000002218 hypoglycaemic effect Effects 0.000 description 3
- 125000002883 imidazolyl group Chemical group 0.000 description 3
- 230000000302 ischemic effect Effects 0.000 description 3
- 125000001786 isothiazolyl group Chemical group 0.000 description 3
- 125000000842 isoxazolyl group Chemical group 0.000 description 3
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 125000002971 oxazolyl group Chemical group 0.000 description 3
- 125000003373 pyrazinyl group Chemical group 0.000 description 3
- 125000003226 pyrazolyl group Chemical group 0.000 description 3
- 125000002098 pyridazinyl group Chemical group 0.000 description 3
- 125000004076 pyridyl group Chemical group 0.000 description 3
- 125000000714 pyrimidinyl group Chemical group 0.000 description 3
- 125000000168 pyrrolyl group Chemical group 0.000 description 3
- 125000000335 thiazolyl group Chemical group 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- RIIVBOIBIOLLPO-UHFFFAOYSA-N 2-phthalazin-1-ylacetic acid Chemical compound C1=CC=C2C(CC(=O)O)=NN=CC2=C1 RIIVBOIBIOLLPO-UHFFFAOYSA-N 0.000 description 2
- 208000035150 Hypercholesterolemia Diseases 0.000 description 2
- 208000013016 Hypoglycemia Diseases 0.000 description 2
- 208000001647 Renal Insufficiency Diseases 0.000 description 2
- 229940100389 Sulfonylurea Drugs 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- 125000003282 alkyl amino group Chemical group 0.000 description 2
- 210000000709 aorta Anatomy 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 125000005708 carbonyloxy group Chemical group [*:2]OC([*:1])=O 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 238000007675 cardiac surgery Methods 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 201000006370 kidney failure Diseases 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 125000002757 morpholinyl group Chemical group 0.000 description 2
- 208000037891 myocardial injury Diseases 0.000 description 2
- 125000004043 oxo group Chemical group O=* 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 125000004193 piperazinyl group Chemical group 0.000 description 2
- 125000003386 piperidinyl group Chemical group 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 2
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 2
- 125000002755 pyrazolinyl group Chemical group 0.000 description 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 2
- 230000010410 reperfusion Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 210000005166 vasculature Anatomy 0.000 description 2
- RAXXELZNTBOGNW-UHFFFAOYSA-N 1H-imidazole Chemical compound C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 1
- VMJNTFXCTXAXTC-UHFFFAOYSA-N 2,2-difluoro-1,3-benzodioxole-5-carbonitrile Chemical group C1=C(C#N)C=C2OC(F)(F)OC2=C1 VMJNTFXCTXAXTC-UHFFFAOYSA-N 0.000 description 1
- VFTOHJFKIJLYKN-UHFFFAOYSA-N 7-nitro-9h-fluoren-2-ol Chemical group [O-][N+](=O)C1=CC=C2C3=CC=C(O)C=C3CC2=C1 VFTOHJFKIJLYKN-UHFFFAOYSA-N 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 1
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 1
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 108010064733 Angiotensins Proteins 0.000 description 1
- 102000015427 Angiotensins Human genes 0.000 description 1
- 208000031104 Arterial Occlusive disease Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 description 1
- 208000006029 Cardiomegaly Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 208000017701 Endocrine disease Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 1
- 206010053240 Glycogen storage disease type VI Diseases 0.000 description 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 229940122355 Insulin sensitizer Drugs 0.000 description 1
- OWYWGLHRNBIFJP-UHFFFAOYSA-N Ipazine Chemical compound CCN(CC)C1=NC(Cl)=NC(NC(C)C)=N1 OWYWGLHRNBIFJP-UHFFFAOYSA-N 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- 208000007177 Left Ventricular Hypertrophy Diseases 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- 208000004531 Renal Artery Obstruction Diseases 0.000 description 1
- 206010038378 Renal artery stenosis Diseases 0.000 description 1
- 102100028255 Renin Human genes 0.000 description 1
- 108090000783 Renin Proteins 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 206010042434 Sudden death Diseases 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- CKUAXEQHGKSLHN-UHFFFAOYSA-N [C].[N] Chemical compound [C].[N] CKUAXEQHGKSLHN-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 150000001243 acetic acids Chemical class 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229960002478 aldosterone Drugs 0.000 description 1
- 125000005115 alkyl carbamoyl group Chemical group 0.000 description 1
- 239000003888 alpha glucosidase inhibitor Substances 0.000 description 1
- HXXFSFRBOHSIMQ-VFUOTHLCSA-N alpha-D-glucose 1-phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(O)=O)[C@H](O)[C@@H](O)[C@@H]1O HXXFSFRBOHSIMQ-VFUOTHLCSA-N 0.000 description 1
- XKMRRTOUMJRJIA-UHFFFAOYSA-N ammonia nh3 Chemical compound N.N XKMRRTOUMJRJIA-UHFFFAOYSA-N 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 208000021328 arterial occlusion Diseases 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 150000004283 biguanides Chemical class 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical group C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 239000007833 carbon precursor Substances 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000001627 cerebral artery Anatomy 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 230000001667 episodic effect Effects 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000004110 gluconeogenesis Effects 0.000 description 1
- 150000002303 glucose derivatives Chemical class 0.000 description 1
- 230000010030 glucose lowering effect Effects 0.000 description 1
- 229950010772 glucose-1-phosphate Drugs 0.000 description 1
- 208000007345 glycogen storage disease Diseases 0.000 description 1
- 201000004510 glycogen storage disease VI Diseases 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 125000001475 halogen functional group Chemical group 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000005003 heart tissue Anatomy 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 1
- 201000008980 hyperinsulinism Diseases 0.000 description 1
- 208000006575 hypertriglyceridemia Diseases 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- DOTMOQHOJINYBL-UHFFFAOYSA-N molecular nitrogen;molecular oxygen Chemical compound N#N.O=O DOTMOQHOJINYBL-UHFFFAOYSA-N 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000003538 oral antidiabetic agent Substances 0.000 description 1
- 229940127209 oral hypoglycaemic agent Drugs 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 208000028591 pheochromocytoma Diseases 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 230000001292 preischemic effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000005167 vascular cell Anatomy 0.000 description 1
- 230000006444 vascular growth Effects 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Superheterodyne Receivers (AREA)
- Enzymes And Modification Thereof (AREA)
- Noise Elimination (AREA)
- Indole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6636597P | 1997-11-21 | 1997-11-21 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AP9801401A0 AP9801401A0 (en) | 1998-12-31 |
| AP911A true AP911A (en) | 2000-12-07 |
Family
ID=22069038
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| APAP/P/1998/001401A AP911A (en) | 1997-11-21 | 1998-11-19 | Combinatin of aldose reductase inhibitor and a glycogen phosphorylase inhibitor. |
Country Status (38)
| Country | Link |
|---|---|
| EP (1) | EP1032424B9 (de) |
| JP (1) | JP2002504478A (de) |
| KR (2) | KR20010032304A (de) |
| CN (1) | CN1279617A (de) |
| AP (1) | AP911A (de) |
| AR (1) | AR016423A1 (de) |
| AT (1) | ATE205403T1 (de) |
| AU (1) | AU733304B2 (de) |
| BG (1) | BG104435A (de) |
| BR (1) | BR9814698A (de) |
| CA (1) | CA2310069A1 (de) |
| DE (1) | DE69801680T2 (de) |
| DK (1) | DK1032424T3 (de) |
| DZ (1) | DZ2656A1 (de) |
| EA (1) | EA002365B1 (de) |
| ES (1) | ES2161548T3 (de) |
| GR (1) | GR3037071T3 (de) |
| GT (1) | GT199800166A (de) |
| HR (1) | HRP20000327A2 (de) |
| HU (1) | HUP0100272A3 (de) |
| ID (1) | ID24524A (de) |
| IL (1) | IL135713A0 (de) |
| IS (1) | IS5453A (de) |
| MA (1) | MA26568A1 (de) |
| NO (1) | NO20002164L (de) |
| OA (1) | OA11379A (de) |
| PA (1) | PA8462301A1 (de) |
| PE (1) | PE135399A1 (de) |
| PL (1) | PL340643A1 (de) |
| PT (1) | PT1032424E (de) |
| SK (1) | SK7222000A3 (de) |
| TN (1) | TNSN98211A1 (de) |
| TR (1) | TR200001451T2 (de) |
| UA (1) | UA57811C2 (de) |
| UY (1) | UY25258A1 (de) |
| WO (1) | WO1999026659A1 (de) |
| YU (1) | YU30700A (de) |
| ZA (1) | ZA9810636B (de) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2535700A (en) * | 1999-02-12 | 2000-08-29 | Novo Nordisk A/S | Use of pyrrolidine derivatives for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of obesity or appetite regulation |
| PT1741445E (pt) | 2000-01-21 | 2013-11-11 | Novartis Ag | Combinações incluindo inibidores de dipeptidilpeptidase-iv e agentes antidiabéticos |
| CO5271699A1 (es) * | 2000-01-24 | 2003-04-30 | Pfizer Prod Inc | Procedimiento para el tratamiento de cardiomiopatia utilizando inhibidores de la glucogeno fosforilasa |
| US6570013B2 (en) | 2000-02-16 | 2003-05-27 | Pfizer Inc | Salts of zopolrestat |
| US6395767B2 (en) | 2000-03-10 | 2002-05-28 | Bristol-Myers Squibb Company | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
| IL144507A0 (en) * | 2000-07-31 | 2002-05-23 | Pfizer Prod Inc | Use of glycogen phosphorylase inhibitors to inhibit tumor growth |
| WO2002098429A1 (en) * | 2001-06-07 | 2002-12-12 | Pfizer Products Inc. | Ethanolamine, diethanolamine or triethanolamine salt of zopolrestat |
| GB0205166D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
| GB0205176D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
| GB0205175D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
| GB0205170D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
| GB0205162D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
| GB0205165D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
| US7057046B2 (en) | 2002-05-20 | 2006-06-06 | Bristol-Myers Squibb Company | Lactam glycogen phosphorylase inhibitors and method of use |
| CA2392486A1 (en) | 2002-07-05 | 2002-12-08 | Duchesnay Inc. | Pharmaceutical dosage form bearing pregnancy-friendly indicia |
| US7098235B2 (en) | 2002-11-14 | 2006-08-29 | Bristol-Myers Squibb Co. | Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds |
| US7576121B2 (en) | 2003-11-12 | 2009-08-18 | Phenomix Corporation | Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV |
| US7317109B2 (en) | 2003-11-12 | 2008-01-08 | Phenomix Corporation | Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV |
| US7767828B2 (en) | 2003-11-12 | 2010-08-03 | Phenomix Corporation | Methyl and ethyl substituted pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV |
| EP1997533B8 (de) | 2003-11-12 | 2014-10-29 | Sino-Med International Alliance, Inc. | Heterocyclische Boronsäureverbindungen, Dipeptidylpeptidase IV Inhibitoren |
| EP1778220A1 (de) | 2004-07-12 | 2007-05-02 | Phenomix Corporation | Eingezwängte cyano-verbindungen |
| US7365061B2 (en) | 2004-11-15 | 2008-04-29 | Bristol-Myers Squibb Company | 2-Amino-3-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors |
| WO2006055462A1 (en) | 2004-11-15 | 2006-05-26 | Bristol-Myers Squibb Company | 2-amino-4-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors |
| WO2006055435A1 (en) | 2004-11-15 | 2006-05-26 | Bristol-Myers Squibb Company | 2-aminonaphthalene derivatives and related glycogen phosphorylase inhibitors |
| WO2006053274A2 (en) | 2004-11-15 | 2006-05-18 | Bristol-Myers Squibb Company | 2-amino-1-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors |
| US20060235028A1 (en) | 2005-04-14 | 2006-10-19 | Li James J | Inhibitors of 11-beta hydroxysteroid dehydrogenase type I |
| US7825139B2 (en) | 2005-05-25 | 2010-11-02 | Forest Laboratories Holdings Limited (BM) | Compounds and methods for selective inhibition of dipeptidyl peptidase-IV |
| HRP20140091T4 (hr) | 2005-09-14 | 2021-12-24 | Takeda Pharmaceutical Company Limited | Davanje inhibitora dipeptidil peptidaze |
| EP2046753A2 (de) | 2006-07-06 | 2009-04-15 | Brystol-Myers Squibb Company | Pyridon/hydroxypyridin-11-beta-hydroxysteroid-dehydrogenase-hemmer vom typ i |
| US7727978B2 (en) | 2006-08-24 | 2010-06-01 | Bristol-Myers Squibb Company | Cyclic 11-beta hydroxysteroid dehydrogenase type I inhibitors |
| CN101687873A (zh) | 2007-04-17 | 2010-03-31 | 百时美施贵宝公司 | 具有稠合杂环的11β-羟基类固醇Ⅰ型脱氢酶抑制剂 |
| EP2144902B1 (de) | 2007-05-04 | 2012-05-16 | Bristol-Myers Squibb Company | An gpr119-g-protein gekoppelte [6,6]und [6,7]-bicyclische rezeptoragonisten |
| JP2010526146A (ja) | 2007-05-04 | 2010-07-29 | ブリストル−マイヤーズ スクイブ カンパニー | ［６，５］−二環式ｇｐｒ１１９ｇタンパク質結合受容体アゴニスト |
| CA2693444A1 (en) | 2007-07-17 | 2009-01-22 | Bristol-Myers Squibb Company | Method for modulating gpr119 g protein-coupled receptor and selected compounds |
| TW201006821A (en) | 2008-07-16 | 2010-02-16 | Bristol Myers Squibb Co | Pyridone and pyridazone analogues as GPR119 modulators |
| WO2011041293A1 (en) | 2009-09-30 | 2011-04-07 | Takeda Pharmaceutical Company Limited | Pyrazolo [1, 5-a] pyrimidine derivatives as apoptosis signal-regulating kinase 1 inhibitors |
| CN102834393B (zh) | 2010-02-03 | 2015-07-22 | 武田药品工业株式会社 | 细胞凋亡信号调节激酶1抑制剂 |
| US8415367B2 (en) | 2010-04-08 | 2013-04-09 | Bristol-Myers Squibb Company | Pyrimidinylpiperidinyloxypyridinone analogues as GPR119 modulators |
| ES2559209T3 (es) | 2010-04-14 | 2016-02-11 | Bristol-Myers Squibb Company | Nuevos activadores de la glucocinasa y métodos de uso de los mismos |
| WO2011140161A1 (en) | 2010-05-06 | 2011-11-10 | Bristol-Myers Squibb Company | Benzofuranyl analogues as gpr119 modulators |
| BR112012028445A2 (pt) | 2010-05-06 | 2016-07-19 | Bristol Myers Squibb Co | compostos de heteroarila bicíclica como moduladores de gpr119 |
| HUE026715T2 (en) | 2011-01-20 | 2016-07-28 | Bionevia Pharmaceuticals Inc | Modified release pharmaceutical composition comprising Epalrestat or a derivative thereof and methods of their use |
| EP2850073B1 (de) | 2012-05-16 | 2017-07-19 | Bristol-Myers Squibb Company | Pyrimidinylpiperidinyloxypyridon-analoga als gpr119-modulatoren |
| US9580422B2 (en) | 2013-10-22 | 2017-02-28 | Bristol-Myers Squibb Company | Isotopically labeled triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors |
| KR102513342B1 (ko) | 2016-07-22 | 2023-03-22 | 브리스톨-마이어스 스큅 컴퍼니 | 글루코키나제 활성화제 및 그의 사용 방법 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0624369A1 (de) * | 1993-05-10 | 1994-11-17 | Pfizer Inc. | Verfahren zur Senkung von Lipidblutspiegel |
| WO1996039384A1 (en) * | 1995-06-06 | 1996-12-12 | Pfizer, Inc. | Substituted n-(indole-2-carbonyl)-glycinamides and derivatives as glycogen phosphorylase inhibitors |
| WO1996039385A1 (en) * | 1995-06-06 | 1996-12-12 | Pfizer Inc. | Substituted n-(indole-2-carbonyl-) amides and derivatives as glycogen phosphorylase inhibitors |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4825448A (en) * | 1986-08-07 | 1989-04-25 | International Mobile Machines Corporation | Subscriber unit for wireless digital telephone system |
| DE3889326D1 (de) * | 1988-05-27 | 1994-06-01 | Itt Ind Gmbh Deutsche | Korrekturschaltung für ein digitales Quadratur-Signalpaar. |
-
1998
- 1998-02-11 UA UA2000052869A patent/UA57811C2/uk unknown
- 1998-10-27 GT GT199800166A patent/GT199800166A/es unknown
- 1998-10-28 PA PA19988462301A patent/PA8462301A1/es unknown
- 1998-11-02 DE DE69801680T patent/DE69801680T2/de not_active Expired - Fee Related
- 1998-11-02 KR KR1020007005514A patent/KR20010032304A/ko not_active Ceased
- 1998-11-02 SK SK722-2000A patent/SK7222000A3/sk unknown
- 1998-11-02 AU AU95558/98A patent/AU733304B2/en not_active Ceased
- 1998-11-02 DK DK98949193T patent/DK1032424T3/da active
- 1998-11-02 YU YU30700A patent/YU30700A/sh unknown
- 1998-11-02 WO PCT/IB1998/001752 patent/WO1999026659A1/en not_active Ceased
- 1998-11-02 PL PL98340643A patent/PL340643A1/xx unknown
- 1998-11-02 EA EA200000433A patent/EA002365B1/ru not_active IP Right Cessation
- 1998-11-02 IL IL13571398A patent/IL135713A0/xx unknown
- 1998-11-02 AT AT98949193T patent/ATE205403T1/de not_active IP Right Cessation
- 1998-11-02 JP JP2000521860A patent/JP2002504478A/ja active Pending
- 1998-11-02 HR HR20000327A patent/HRP20000327A2/hr not_active Application Discontinuation
- 1998-11-02 CA CA002310069A patent/CA2310069A1/en not_active Abandoned
- 1998-11-02 PT PT81300054T patent/PT1032424E/pt unknown
- 1998-11-02 BR BR9814698-0A patent/BR9814698A/pt not_active IP Right Cessation
- 1998-11-02 CN CN98811329A patent/CN1279617A/zh active Pending
- 1998-11-02 ID IDW20000958A patent/ID24524A/id unknown
- 1998-11-02 TR TR2000/01451T patent/TR200001451T2/xx unknown
- 1998-11-02 EP EP98949193A patent/EP1032424B9/de not_active Expired - Lifetime
- 1998-11-02 HU HU0100272A patent/HUP0100272A3/hu unknown
- 1998-11-02 ES ES98949193T patent/ES2161548T3/es not_active Expired - Lifetime
- 1998-11-16 PE PE1998001113A patent/PE135399A1/es not_active Application Discontinuation
- 1998-11-18 DZ DZ980266A patent/DZ2656A1/xx active
- 1998-11-18 TN TNTNSN98211A patent/TNSN98211A1/fr unknown
- 1998-11-19 AP APAP/P/1998/001401A patent/AP911A/en active
- 1998-11-19 MA MA25356A patent/MA26568A1/fr unknown
- 1998-11-19 UY UY25258A patent/UY25258A1/es not_active Application Discontinuation
- 1998-11-19 AR ARP980105883A patent/AR016423A1/es not_active Application Discontinuation
- 1998-11-20 ZA ZA9810636A patent/ZA9810636B/xx unknown
-
1999
- 1999-05-07 KR KR1020007013394A patent/KR100661214B1/ko not_active Expired - Fee Related
-
2000
- 2000-04-14 IS IS5453A patent/IS5453A/is unknown
- 2000-04-27 NO NO20002164A patent/NO20002164L/no not_active Application Discontinuation
- 2000-05-12 OA OA1200000137A patent/OA11379A/en unknown
- 2000-05-15 BG BG104435A patent/BG104435A/bg unknown
-
2001
- 2001-10-30 GR GR20010401943T patent/GR3037071T3/el not_active IP Right Cessation
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0624369A1 (de) * | 1993-05-10 | 1994-11-17 | Pfizer Inc. | Verfahren zur Senkung von Lipidblutspiegel |
| WO1996039384A1 (en) * | 1995-06-06 | 1996-12-12 | Pfizer, Inc. | Substituted n-(indole-2-carbonyl)-glycinamides and derivatives as glycogen phosphorylase inhibitors |
| WO1996039385A1 (en) * | 1995-06-06 | 1996-12-12 | Pfizer Inc. | Substituted n-(indole-2-carbonyl-) amides and derivatives as glycogen phosphorylase inhibitors |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AP911A (en) | Combinatin of aldose reductase inhibitor and a glycogen phosphorylase inhibitor. | |
| AU706628B2 (en) | Treatment of arteriosclerosis and xanthoma | |
| US7166625B2 (en) | Method for treating fibrotic diseases and other indications | |
| US20030027820A1 (en) | Method for treating fibrotic diseases or other indications V | |
| ZA200608886B (en) | Indolyl derivatives as liver-X-receptor modulators | |
| EA015169B1 (ru) | Применение ингибиторов дипептидилпептидазы | |
| EA017799B1 (ru) | Применение 2-[6-(3-аминопиперидин-1-ил)-3-метил-2,4-диоксо-3,4-дигидро-2н-пиримидин-1-илметил]-4-фторбензонитрила | |
| ZA200607491B (en) | Tetrahydrocarbazoles and derivatives | |
| JP2010248205A (ja) | 強皮症の治療のためのベンザゾール誘導体 | |
| CN1771040B (zh) | 糖尿病治疗药 | |
| CA2448294A1 (en) | Method for treating fibrotic diseases or other indications vi | |
| AU2025256076A1 (en) | Combination Therapy Methods, Compositions and Kits | |
| RU2448093C2 (ru) | Производные пиридина для лечения метаболических нарушений, связанных с устойчивостью к действию инсулина или гипергликемией | |
| US20070043016A1 (en) | Method of treating fibrotic diseases or other indications with imidazolium agents | |
| AU2002241670B2 (en) | Method for treating glaucoma IB | |
| JP2000086629A (ja) | 新規な酸化窒素放出化合物 | |
| KR20010108387A (ko) | 당뇨병 치료제 | |
| CA2511735C (en) | A method for treating renal failure using levosimendan or its metabolite or salts thereof | |
| TW202308611A (zh) | 包含１－（３－氰基－１－異丙基－吲哚－５－基）吡唑－４－甲酸之醫藥組成物 | |
| WO2006132196A1 (ja) | β３作動薬を含有する新規な医薬 | |
| WO2002072098A1 (en) | Method of treatment | |
| KR20080028382A (ko) | 레닌 억제제와 인슐린 분비 증진제 또는 인슐린 증감제의조합물 | |
| CA2417883A1 (en) | Pharmaceutical composition comprising metformin and a 5-phenoxyalkyl-2,4-thiazolidinedione-type derivative | |
| Bell | Drugs for cardiovascular risk reduction in the diabetic patient | |
| EP1864663A1 (de) | Mittel zur prävention und/oder behandlung von rheumatoider arthritis |